BOULDER, Colo. & BEVERLY, Mass. — Today, Enzymatics launches two new targeted next generation sequencing assays for detecting and identifying fusions in NTRK and FGFR gene families. The FusionPlex™ NTRK and FGFR assays use Enzymatics’ proprietary NGS-based fusion detection technology, Anchored Multiplex PCR (AMP™), to detect and identify fusions and mutations without prior knowledge of breakpoints or fusion partners from minute amounts of various sample types. The panels will join the ALK, RET, ROS1 panel, the Heme panel, and the Sarcoma panel as the newest additions to the Archer™ FusionPlex™ product line.

Archer™ FusionPlex™ NTRK panel www.enzymatics.com/archer/ntrk

Archer™ FusionPlex™ FGFR panel www.enzymatics.com/archer/fgfr

About Archer™ by Enzymatics

Archer™ by Enzymatics provides an all-encompassing NGS solution from library preparation to analysis and reporting. Archer™ utilizes a simple lyophilized workflow optimized for high-volume labs to minimize hands on time and chance of contamination in library preparation. The AMP™-enabled FusionPlex™ panels are target enrichment assays used to create libraries for Illumina® or Ion Torrent™ sequencing from as little as 20ng nucleic acid extracted from FFPE. Once sequenced, the Archer™ Analysis Pipeline provides comprehensive analysis with embedded QC metrics and read-visualization to accurately detect and identify known and novel fusions.

Note: Archer™ kits and analysis software are for research use only and not for use in diagnostic procedures.

About Enzymatics

Enzymatics is a leading producer of sample preparation reagents, assays, kits and software for life science research and applied science customers worldwide. We are experts in the fields of DNA sequencing and PCR, and our business units include:

· Reagents

· Supply Chain Solutions

· Applied Science

Our passion for quality, responsiveness and flexibility is catalyzing the genomic healthcare revolution. www.enzymatics.com